Sugi Predict

Sugi Predict / Targets / ANPEP

ANPEP

Aminopeptidase N · P15144 · ANPEP on Sugi Atlas →

73,576 patent compounds predicted against ANPEP, 36,039 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL200955 SCHEMBL200955 0.51 16/20
SCHEMBL255253 SCHEMBL255253 0.50 11/20
Puromycin Puromycin (SCHEMBL4570) 1.00 10/20
Puromycin Puromycin (SCHEMBL4317) 0.99 10/20
SCHEMBL254427 SCHEMBL254427 0.41 9/20
SCHEMBL251692 SCHEMBL251692 0.49 8/20
SCHEMBL57183 SCHEMBL57183 0.58 7/20
SCHEMBL201374 SCHEMBL201374 0.54 7/20
SCHEMBL246046 SCHEMBL246046 0.46 7/20
SCHEMBL254610 SCHEMBL254610 0.41 7/20
SCHEMBL254790 SCHEMBL254790 0.40 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL56160) 0.40 7/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL56161) 0.40 7/20
SCHEMBL173289 SCHEMBL173289 1.00 6/20
SCHEMBL74870 SCHEMBL74870 0.81 6/20
SCHEMBL74871 SCHEMBL74871 0.81 6/20
SCHEMBL56311 SCHEMBL56311 0.65 6/20
SCHEMBL74974 SCHEMBL74974 0.62 6/20
SCHEMBL74975 SCHEMBL74975 0.62 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL56763) 0.61 6/20

Clinical trials — most relevant to ANPEP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock PHASE4COMPLETED
NT-proBNP in the Optimization of Treatment After Recent Acute Heart Failure Trial PHASE4COMPLETED
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI PHASE3COMPLETED
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients. PHASE3COMPLETED
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer PHASE2WITHDRAWN
The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man PHASE2COMPLETED
Roflumilast in Non-CF Bronchiectasis Study (2019) PHASE2COMPLETED
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
CoVID-19 Plasma in Treatment of COVID-19 Patients EARLY_PHASE1COMPLETED
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers EARLY_PHASE1COMPLETED
A Cut-off Value Study of N-terminal Brain Natriuretic Peptide （Chemiluminescence Method） nanCOMPLETED
Protein Digestion and Amino Acid Absorption in the Aging Gastrointestinal Tract nanCOMPLETED
Ankle Brachial Index Versus Conventional Cardiac Risk Indices nanUNKNOWN
DPP4 Activity, Microvascular Reactivity and Inflammation nanCOMPLETED
Neutral Endopeptidase for Early Detection of Acute Kidney Injury After Cardiac Surgery nanCOMPLETED
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia. nanCOMPLETED
Ovarian Reserve and Matrix Metalloproteinases nanCOMPLETED
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings nanUNKNOWN
ULtrafiltration-Rate Induced CArdiac Strain (ULRICA) - Study nanRECRUITING
Clearance of Vasoactive Metabolites With Blood Purification nanRECRUITING
Biomarker Guided Discharge of Heart Failure Patients nanRECRUITING
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19). nanCOMPLETED
Impact of Sacubitril/Valsartan on Quality of Life and Mortality of CKD vs Non-CKD in Heart Failure Patients nanCOMPLETED
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients nanAPPROVED_FOR_MARKETING
Apelin12 in Acne Vulgaris nanUNKNOWN
B-type NAtriuretic Peptide In Critically Ill : A Multicentric Diagnostic Study (B-rAPID) nanUNKNOWN
NATriuretic Response to Expansion and dIUretics in huMans With Heart Failure nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ANPEP binder may also engage these)

ProteinNameSimilarity
P15684 — 1.000 P15684 →
P97449 — 1.000 P97449 →
P79098 — 1.000 P79098 →
P15541 — 1.000 P15541 →
P79171 — 1.000 P79171 →
P15145 — 1.000 P15145 →
P50123 — 1.000 P50123 →
O57579 — 1.000 O57579 →
P16406 — 1.000 P16406 →
P79143 — 1.000 P79143 →
ENPEP Glutamyl aminopeptidase 0.999 landscape →
A5HUI5 — 0.996 A5HUI5 →
ERAP1 Endoplasmic reticulum aminopeptidase 1 0.996 landscape →
A6QPT7 — 0.995 A6QPT7 →
Q32LQ0 — 0.994 Q32LQ0 →
D3UW23 — 0.994 D3UW23 →
Q5RFP3 — 0.993 Q5RFP3 →
Q95334 — 0.993 Q95334 →
Q9JJ22 — 0.993 Q9JJ22 →
P32454 — 0.993 P32454 →
ERAP2 Endoplasmic reticulum aminopeptidase 2 0.992 landscape →
Q6K4E7 — 0.992 Q6K4E7 →
Q0J5V5 — 0.991 Q0J5V5 →
Q6Z6L4 — 0.991 Q6Z6L4 →
MGAM Maltase-glucoamylase 0.991 landscape →
Q9EQH2 — 0.990 Q9EQH2 →
Q10737 — 0.990 Q10737 →
Q59KZ1 — 0.990 Q59KZ1 →
NPEPPS Puromycin-sensitive aminopeptidase 0.989 landscape →
Q7Q2T8 — 0.988 Q7Q2T8 →